Pacific Medical Journal
Tihookeanskij medicinskij žurnal

ISSN 1609-1175 (Print)

eng | рус

Preview

Pacific Medical Journal

Advanced search

Archives

Analysis of matrix metallopeptidase 9 (MMP-9), tissue inhibitor of metalloproteinases type 1 (TIMP-1) and MMP-9/TIMP-1 complex in patients with acute myocardial infarction after percutaneous coronary interventions

N. I. Grachev, V. E. Krasnikov, E. P. Turmova, E. V. Markelova, V. Yu. Rublev, S. A. Nazarenko

https://doi.org/10.17238/PmJ1609-1175.2018.4.45-48

Full Text:

PDF (Rus) |

Generate QR code

Abstract

Objective. The objective of the study was to identify additional markers of complications of percutaneous coronary interventions in patients with acute myocardial infarction Methods. We analyzed the serum content MMP-9, TIMP-1, and MMP-9/TIMP-1 complex in 86 patients aged 41-74 with acute myocardial infarction before and after percutaneous coronary intervention. Results. The serum levels of MmP-9 and TIMP-1 in patients with acute myocardial infarction are significantly higher than in healthy individuals, while the MMP-9/TIMP-1 complex, in contrast, is lower than in the control group. The dynamics of serum concentration of MMP-9 and TIMP-1 after the intervention had a different picture: by the 7^th day, the level of MMP-9 increased, while the TIMP-1 values, on the contrary, decreased. Conclusions. Our study proved the possibility of using the serum concentration of MMP-9 (426.8-978.4 ng/ml) as a predictor of early postoperative complications in patients with acute myocardial infarction after percutaneous coronary interventions.

Keywords

ROC-анализ, extracellular matrix proteinase, coronary atherosclerosis, complications of endovascular interventions, ROC curve analysis

About the Authors

N. I. Grachev

Pacific State Medical University
Russian Federation

V. E. Krasnikov

Pacific State Medical University
Russian Federation

E. P. Turmova

Pacific State Medical University
Russian Federation

E. V. Markelova

Pacific State Medical University
Russian Federation

V. Yu. Rublev

Primorye Regional Clinical Hospital No. 1
Russian Federation

S. A. Nazarenko

Pacific State Medical University
Russian Federation

References

1. Ахмедов В.А., Долгих В.Т., Наумов Д.В., Нечипоренко Н.А. Клиническое значение матриксных металлопротеиназ при сердечно-сосудистой патологии // Патологическая физиология и экспериментальная терапия. 2013. № 2. С. 77-79

2. Говорин А.В., Рацина Е.В., Соколова Н.А. Изменения показателей матриксных металлопротеиназ и их тканевых ингибиторов при различных формах ишемической болезни сердца // Сибирский мед. журн. (Иркутск). 2014. Т. 124, № 1. С. 27-32

3. Печерина Т.Б., Груздева О.В., Кашталап В.В., Барбараш О.Л. Роль матриксных металлопротеиназ в оценке прогноза у больных инфарктом миокарда с подъемом сегмента ST в период пребывания в стационаре // Кардиология. 2013. Т. 53, № 6. С. 18-24

4. Пономарь Е.Г., Сыркин А.Л., Гусев Д.Е., Андреев Д.А. Маркеры воспаления и долгосрочный прогноз у больных с острым коронарным синдромом и стабильной формой ишемической болезни сердца // Кардиология и сердечно-сосудистая хирургия. 2011. Т. 4, № 6. С. 10-15

5. Рогова Л.Н., Шестернина Н.В., Замечник Т.В., Фастова И.А. Матриксные металлопротеиназы, их роль в физиологических и патологических процессах // Вестник новых медицинских технологий. 2011. Т. 18, № 2. С. 86-89

6. Силаев А.А., Турмова Е.П., Маркелова Е.В. [и др.]. Анализ эффективности цитокинотерапии в послеоперационном периоде у пациентов с коронарным атеросклерозом // Тихоокеанский медицинский журнал. 2013. № 3. С. 18-21

7. Bigg H.F., Rowan A.D., Barker M.D., Cawston T.E. Activity of matrix metalloproteinase-9 against native collagen types I and III // FEBS J. 2007. Vol. 274. No. 5. P. 1246-1255.

8. Dinh W., Scheffold T., Bansemir L. [et al.]. Increased serum levels of tissue inhibitor of metalloproteinase-1 in patients with acute myocardial infarction // International Heart Journal. 2009. Vol. 50. No. 4. P. 421-431.

9. Furenes E.B., Opstad T.B., Solheim S. [et al.]. The influence of autologous bone marrow stem cell transplantation on matrix metalloproteinases in patients treated for acute ST-elevation myocardial infarction // Mediators Inflamm. 2014. doi: 10.1155/2014/385901.

10. Jefferis B.J., Whincup P., Welsh P. [et al.]. Prospective study of matrix metalloproteinase-9 and risk of myocardial infarction and stroke in older men and women // Atherosclerosis. 2010. Vol. 208, No. 2. P. 557-563.

11. Opstad T.B, Arnesen H., Pettersen A.A. [et al.]. The MMP-9-1562 C/T polymorphism in the presence of metabolic syndrome increases the risk of clinical events in patients with coronary artery disease // PLoS One. 2014. Vol. 9, No. 9. P. e106816.

12. Phatharajaree W., Phrommintikul A., Chattipakorn N. Matrix metalloproteinases and myocardial infarction // Can. J. Cardiol. 2007. Vol. 23, No. 9. P. 727-733.

13. Wang Y., Fu R., Wang Z. [et al.]. Assessing the quality of care for patients with acute myocardial infarction in China // Clin. Cardiol. 2015. Vol. 38, No. 6. P. 327-332.

Review

For citations:

Grachev N.I., Krasnikov V.E., Turmova E.P., Markelova E.V., Rublev V.Yu., Nazarenko S.A. Analysis of matrix metallopeptidase 9 (MMP-9), tissue inhibitor of metalloproteinases type 1 (TIMP-1) and MMP-9/TIMP-1 complex in patients with acute myocardial infarction after percutaneous coronary interventions. Pacific Medical Journal. 2018;(4):45-48. (In Russ.) https://doi.org/10.17238/PmJ1609-1175.2018.4.45-48

Views: 352

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 License.

ISSN 1609-1175 (Print)